Overview

A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 Study Evaluating the Safety of ABT-263 in Combination with Etoposide/Cisplatin in Subjects with Small Cell Lung Cancer (SCLC).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Genentech, Inc.
Treatments:
Cisplatin
Etoposide
Etoposide phosphate
Navitoclax